Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$11.13 - $16.28 $769,695 - $1.13 Million
-69,155 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$9.79 - $16.72 $677,027 - $1.16 Million
69,155 New
69,155 $859,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Eco R1 Capital, LLC Portfolio

Follow Eco R1 Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.